Anavex Life Sciences Corp (AVXL)

[bas2020]

I believe Missling's comment about efficacy being more pronounced for the mildly afflicted has much to do with the outliers. The ones at higher concentrations not stabilized were likely advanced in their disease. While the one performing well on a lower concentration was likely less advanced (mild).

Sure, DNA, RNA, gut biome, etc., could be factors within those disease stages, but early treatment would seem to be the biggest factor.